SNMMI 2024 Annual Meeting
Get the latest research and practical clinical applications from the SNMMI 2024 Annual Meeting, including focused coverage on genitourinary cancer data.
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
![PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC](https://mumcdnstorage.blob.core.windows.net/guonc/2024/06/122-GUOnc_YouTube_Sartor_1280x720.jpg)
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
177Lu-PSMA-617 in heavily pretreated patients with late-stage mCRPC provided beneficial antitumor effects.
Intensified RLT with escalation of the first 3 cycles to 10-11 GBq for high-volume mCRPC may increase treatment efficacy.
The use of 89Zr PET/CT and subsequent surgery in patients treated with it demonstrated low radiation exposure levels.
A phase 3 trial offers the first randomized evidence of the benefit of PSMA tandem therapy in patients with mCRPC.
New research provides evidence of 18F-rhPSMA-7 leading to more favorable disease outcomes for patients with BCR after RP.
COBRA trial shows 64Cu-SAR-bisPSMA improves detection of recurrent prostate cancer with high specificity.
![Radioligand Therapy With [177Lu]Lu-PSMA I&T Shows Promising Safety, Efficacy in Elderly Patients With Prostate Cancer](https://mumcdnstorage.blob.core.windows.net/guonc/2023/06/Prostate-Cancer.png)
Study shows [177Lu]Lu-PSMA is safe and effective for elderly patients with mCRPC, improving PSA response and overall survival
PSMA-dRT trial: PSMA PET/CT enhances staging and treatment planning for patients with intermediate/high-risk prostate cancer.
![Promising Phase 3 Trial Results for [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC](https://mumcdnstorage.blob.core.windows.net/guonc/2023/09/Prostate-7.0.png)
The PSMAfore trial shows [177Lu]Lu-PSMA-617 significantly improves rPFS, ORR, and PSA50 in taxane-naive patients with mCRPC.
Advertisement
Advertisement
